Overcoming the challenges of siRNA delivery: Nanoparticle strategies

Current Drug Delivery

Volumn 13, Issue , 2016, Pages

  Shajari, Neda ^a   Mansoori, Behzad ^a   Davudian, Sadaf ^a   Mohammadi, Ali ^a   Baradaran, Behzad ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Chemical modification; Lipid based nanoparticle; Polymeric nanoparticle; RNAi; Systemic delivery

Indexed keywords

ATELOCOLLAGEN; CATIONIC LIPID; CHITOSAN; CYCLODEXTRIN; DENDRIMER; LIPOSOME; MACROGOL; MICRORNA; NANOCARRIER; POLYETHYLENEIMINE; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; LIPID; NANOPARTICLE; POLYMER; STABLE NUCLEIC ACID LIPID NANOPARTICLE;

CHEMICAL MODIFICATION; CONJUGATION; DRUG DEGRADATION; DRUG PENETRATION; ENDOSOME; HUMAN; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; NANOPHARMACEUTICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; RNA TRANSPORT; RNAI THERAPEUTICS; SYSTEMIC THERAPY; DRUG DELIVERY SYSTEM; ENZYMATIC DEGRADATION; IMMUNE SYSTEM; IMMUNOTOXICITY; LIPOSOMAL GENE DELIVERY SYSTEM; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERIZATION; TARGET TISSUE;

EID: 85010465843     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201813666160816105408     Document Type: Review

References (129)

1. Napoli, C.; Lemieux, C.; Jorgensen, R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible cosuppression of homologous genes in trans. The plant cell, 1990, 2(4), 279-289.
2. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature, 1998, 391(6669), 806-811.
3. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411(6836), 494-498.
4. Hannon, G.J. RNA interference. Nature, 2002, 418(6894), 244-251.
5. Sun, J.; Wang, J.; Yang, Z. Supramolecular Assembly Models of siRNA Delivery Systems. Chin. J. Chem., 2015, 33(1), 79-89.
6. Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi therapeutic platforms for lung diseases. Pharmaceuticals, 2013, 6(2), 223-250.
7. Ponnappa, B.C. siRNA for inflammatory diseases. Current opinion in investigational drugs (London, England: 2000), 2009, 10(5), 418-424.
8. Pauley, K.M., Cha, S. Rnai therapeutics in autoimmune disease. Pharmaceuticals, 2013, 6(3), 287-294.
9. Mansoori, B.; Shotorbani, S.S.; Baradaran, B. RNA Interference and its Role in Cancer Therapy. Adv. pharm. bulletin, 2014, 4(4), 313.
10. Zhou, J.; Shum, K.-T.; Burnett, J.C.; Rossi, J.J. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals, 2013, 6(1), 85-107.
11. Bramsen, J.B., Kjems, J., Chemical modification of small interfering RNA, in Antiviral RNAi. 2011, Springer. p. 77-103.
12. Nguyen, J.; Szoka, F.C. Nucleic acid delivery: the missing pieces of the puzzle? Acc. Chem. Res., 2012, 45(7), 1153-1162.
13. Nayak, S., Herzog, R.W. Progress and prospects: immune responses to viral vectors. Gene. Ther., 2010, 17(3), 295-304.
14. Thomas, C.E.; Ehrhardt, A.; Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet., 2003, 4(5), 346-358.
15. Nguyen, D.N.; Green, J.J.; Chan, J.M.; Langer, R.; Anderson, D.G. Polymeric materials for gene delivery and DNA vaccination. Adv. Mater., 2009, 21(8), 847-867.
16. Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.; Stebbing, D.; Crosley, E.J.; Yaworski, E. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol., 2010, 28(2), 172-176.
17. Truong, N.P.; Gu, W.; Prasadam, I.; Jia, Z.; Crawford, R.; Xiao, Y.; Monteiro, M.J. An influenza virus-inspired polymer system for the timed release of siRNA. Nat. commun., 2013, 4, 1902.
18. Hadinoto, K.; Sundaresan, A.; Cheow, W.S. Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur. J. Pharm. Biopharm., 2013, 85(3), 427-443.
19. Jiang, S.; Eltoukhy, A.A.; Love, K.T.; Langer, R.; Anderson, D.G. Lipidoid-coated iron oxide nanoparticles for efficient DNA and siRNA delivery. Nano. Lett., 2013, 13(3), 1059-1064.
20. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol., 2011, 29(4), 341-345.
21. Muller, R.H., Keck, C.M. Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol., 2004, 113(1), 151-170.
22. Volkov, A.A.; Kruglova, N.Y.S.; Meschaninova, M.I.; Venyaminova, A.G.; Zenkova, M.A.; Vlassov, V.V.; Chernolovskaya, E.L. Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides, 2009, 19(2), 191-202.
23. Pérez-Martínez, F.C.; Guerra, J.; Posadas, I.; Ceña, V. Barriers to non-viral vector-mediated gene delivery in the nervous system. Pharm. Res., 2011, 28(8), 1843-1858.
24. Matsumura, Y., Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer res., 1986, 46(12 Part 1), 6387-6392.
25. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. drug target., 2007, 15(7-8), 457-464.
26. Jain, R.K., Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol., 2010, 7(11), 653-664.
27. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconj. Chem., 2010, 21(5), 797-802.
28. Lynch, I.; Salvati, A.; Dawson, K.A. Protein-nanoparticle interactions: what does the cell see? Nat. nanotechnol., 2009, 4(9), 546-547.
29. Scherphof, G.L., Kamps, J.A. The role of hepatocytes in the clearance of liposomes from the blood circulation. Prog Lipid Res, 2001, 40(3), 149-166.
30. Decuzzi, P., Ferrari, M. The receptor-mediated endocytosis of nonspherical particles. Biophys. J., 2008, 94(10), 3790-3797.
31. Shim, M.S., Kwon, Y.J. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv. Drug Deliv. Rev.2012, 64(11), 1046-1059.
32. Dominska, M., Dykxhoorn, D.M. Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci., 2010, 123(8), 1183-1189.
33. Sato, S.; Li, K.; Kameyama, T.; Hayashi, T.; Ishida, Y.; Murakami, S.; Watanabe, T.; Iijima, S.; Sakurai, Y.; Watashi, K. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity, 2015, 42(1), 123-132.
34. Meng, Z.; Zhang, X.; Wu, J.; Pei, R.; Xu, Y.; Yang, D.; Roggendorf, M.; Lu, M. RNAi induces innate immunity through multiple cellular signaling pathways. 2013.
35. Mansoori, B.; Mohammadi, A.; Shir Jang, S.; Baradaran, B. Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA). Artificial cells, nanomedicine, and biotechnology, 2015, 1-8.
36. Shin, D.; Kim, S.I.; Park, M.; Kim, M. Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem. Biophys. Res. Commun., 2007, 364(3), 436-442.
37. Kawai, T., Akira, S., Toll-like Receptor and RIG-1-like Receptor Signaling. Ann. N.Y. Acad. Sci., 2008, 1143(1), 1-20.
38. Sioud, M., Overcoming the Challenges of siRNA Activation of Innate Immunity: Design Better Therapeutic siRNAs, in RNA Interference. 2015, Springer. p. 301-319.
39. Forsbach, A.; Nemorin, J.-G.; Montino, C.; Müller, C.; Samulowitz, U.; Vicari, A.P.; Jurk, M.; Mutwiri, G.K.; Krieg, A.M.; Lipford, G.B. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol., 2008, 180(6), 3729-3738.
40. Jackson, A.L., Linsley, P.S. Recognizing and avoiding siRNA offtarget effects for target identification and therapeutic application. Nat. Rev. Drug Disc., 2010, 9(1), 57-67.
41. Sioud, M.; Furset, G.; Cekaite, L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem. Biophys. Res. Commun., 2007, 361(1), 122-126.
42. Maida, Y.; Kyo, S.; Lassmann, T.; Hayashizaki, Y.; Masutomi, K. Off-target effect of endogenous siRNA derived from RMRP in human cells. Int. J. Mol. Sci., 2013, 14(5), 9305-9318.
43. Nielsen, C.B.; Shomron, N.; Sandberg, R.; Hornstein, E.; Kitzman, J.; Burge, C.B. Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA, 2007, 13(11), 1894-1910.
44. Singh, S.; Narang, A.S.; Mahato, R.I. Subcellular fate and offtarget effects of siRNA, shRNA, and miRNA. Pharm. Res., 2011, 28(12), 2996-3015.
45. Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol., 2006, 2(12), 711-719.
46. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Disc., 2009, 8(2), 129-138.
47. Gao, S.; Dagnaes-Hansen, F.; Nielsen, E.J.B.; Wengel, J.; Besenbacher, F.; Howard, K.A.; Kjems, J. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther., 2009, 17(7), 1225-1233.
48. Peacock, H.; Kannan, A.; Beal, P.A.; Burrows, C.J. Chemical modification of siRNA bases to probe and enhance RNA interference. J. Org. Chem., 2011, 76(18), 7295-7300.
49. Jackson, A.L.; Burchard, J.; Leake, D.; Reynolds, A.; Schelter, J.; Guo, J.; Johnson, J.M.; Lim, L.; Karpilow, J.; Nichols, K. Positionspecific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA, 2006, 12(7), 1197-1205.
50. Snead, N.M.; Escamilla-Powers, J.R.; Rossi, J.J.; McCaffrey, A.P. 5′ Unlocked nucleic acid modification improves siRNA targeting. Molecular Therapy—Nucleic Acids, 2013, 2(7), e103.
51. Martínez-Montero, S.; Deleavey, G.F.; Martín-Pintado, N.; Fakhoury, J.F.; González, C.; Damha, M.J. Locked 2′-Deoxy-2′, 4′-Difluororibo Modified Nucleic Acids: Thermal Stability, Structural Studies, and siRNA Activity. ACS Chem. Biol., 2015, 10(9), 2016-2023.
52. Vilar, G.; Tulla-Puche, J.; Albericio, F. Polymers and drug delivery systems. Curr. Drug Del., 2012, 9(4), 367-394.
53. Grayson, A.C.R.; Doody, A.M.; Putnam, D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res., 2006, 23(8), 1868-1876.
54. Merkel, O.M.; Librizzi, D.; Pfestroff, A.; Schurrat, T.; Buyens, K.; Sanders, N.N.; De Smedt, S.C.; Béhé, M.; Kissel, T. Stability of siRNA polyplexes from poly (ethylenimine) and poly (ethylenimine)-g-poly (ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J. Control. Rel., 2009, 138(2), 148-159.
55. Boeckle, S.; von Gersdorff, K.; van der Piepen, S.; Culmsee, C.; Wagner, E.; Ogris, M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J. Gene med., 2004, 6(10), 1102-1111.
56. Hunter, A.C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Deliv. Rev., 2006, 58(14), 1523-1531.
57. Jere, D.; Jiang, H.-L.; Kim, Y.-K.; Arote, R.; Choi, Y.-J.; Yun, C.-H.; Cho, M.-H.; Cho, C.-S. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int. J. Pharm., 2009, 378(1), 194-200.
58. Huh, M.S.; Lee, S.-Y.; Park, S.; Lee, S.; Chung, H.; Lee, S.; Choi, Y.; Oh, Y.-K.; Park, J.H.; Jeong, S.Y. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J. Control. Rel., 2010, 144(2), 134-143.
59. Nimesh, S. Polyethylenimine as a promising vector for targeted siRNA delivery. Curr. Clin. Pharmacol., 2012, 7(2), 121-130.
60. Ardana, A.; Whittaker, A.K.; McMillan, N.A.; Thurecht, K.J. Polymeric siRNA delivery vectors: knocking down cancers with polymeric-based gene delivery systems. J. Chem. Technol. Biotechnol., 2014.
61. Kukowska-Latallo, J.F.; Bielinska, A.U.; Johnson, J.; Spindler, R.; Tomalia, D.A.; Baker, J.R. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proceed. Nat. Acad. Sci., 1996, 93(10), 4897-4902.
62. Zhou, J.; Neff, C.P.; Liu, X.; Zhang, J.; Li, H.; Smith, D.D.; Swiderski, P.; Aboellail, T.; Huang, Y.; Du, Q. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol. Therapy, 2011, 19(12), 2228-2238.
63. Liu, X.; Rocchi, P.; Peng, L. Dendrimers as non-viral vectors for siRNA delivery. New J. Chem., 2012, 36(2), 256-263.
64. Arima, H.; Motoyama, K.; Higashi, T. Polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for DNA, shRNA and siRNA. Pharmaceutics, 2012, 4(1), 130-148.
65. Xua, L.; Shena, W.; Wang, B.; Wang, X.; Liua, G.; Taoc, Y.; Qia, R. Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells. Curr. Drug Del., 2015.
66. Tiwari, P.; Panthari, P.; Katare, D.P.; Kharkwal, H. Natural polymers in drug delivery. World Journal of Pharmacy and Pharmaceutical Sciences, 2014, 3(9), 1395-1409.
67. Lotfipour, F.; Hallaj-Nezhadi, S.; Valizadeh, H.; Dastmalchi, S.; Baradaran, B.; Jalali, M.B.; Dobakhti, F. Preparation of chitosanplasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. J Pharm Pharm Sci, 2011, 14(2), 181-195.
68. Duttagupta, D.; Jadhav, V.; Kadam, V. Chitosan: a propitious biopolymer for drug delivery. Curr. Drug Del., 2015.
69. Ragelle, H.; Vandermeulen, G.; Préat, V. Chitosan-based siRNA delivery systems. J. Control. Rel., 2013, 172(1), 207-218.
70. Baldrick, P. The safety of chitosan as a pharmaceutical excipient. Regulatory Toxicology and Pharmacology, 2010, 56(3), 290-299.
71. Garcia-Fuentes, M., Alonso, M.J. Chitosan-based drug nanocarriers: where do we stand? Journal of Controlled Release, 2012, 161(2), 496-504.
72. Han, H.D.; Mangala, L.S.; Lee, J.W.; Shahzad, M.M.; Kim, H.S.; Shen, D.; Nam, E.J.; Mora, E.M.; Stone, R.L.; Lu, C. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clinical Cancer Research, 2010, 16(15), 3910-3922.
73. Chaturvedi, K.; Ganguly, K.; Kulkarni, A.R.; Kulkarni, V.H.; Nadagouda, M.N.; Rudzinski, W.E.; Aminabhavi, T.M. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert opin. drug deliv., 2011, 8(11), 1455-1468.
74. Sunshine, J.C.; Bishop, C.J.; Green, J.J. Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Therap. deliv., 2011, 2(4), 493-521.
75. Kanasty, R.; Dorkin, J.R.; Vegas, A.; Anderson, D. Delivery materials for siRNA therapeutics. Nat. mater., 2013, 12(11), 967-977.
76. Heidel, J.D.; Yu, Z.; Liu, J.Y.-C.; Rele, S.M.; Liang, Y.; Zeidan, R.K.; Kornbrust, D.J.; Davis, M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proceed. Nat. Acad. Sci., 2007, 104(14), 5715-5721.
77. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.J.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010, 464(7291), 1067-1070.
78. Zuckerman, J.E.; Gritli, I.; Tolcher, A.; Heidel, J.D.; Lim, D.; Morgan, R.; Chmielowski, B.; Ribas, A.; Davis, M.E.; Yen, Y. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proceed. Nat. Acad. Sci., 2014, 111(31), 11449-11454.
79. Oh, Y.-K., Park, T.G. siRNA delivery systems for cancer treatment. Adv. Drug Del. Rev., 2009, 61(10), 850-862.
80. Takeshita, F.; Minakuchi, Y.; Nagahara, S.; Honma, K.; Sasaki, H.; Hirai, K.; Teratani, T.; Namatame, N.; Yamamoto, Y.; Hanai, K. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proceed. Nat. Acad. Sci. U.S.A., 2005, 102(34), 12177-12182.
81. Yamato, K.; Yamada, T.; Kizaki, M.; Ui-Tei, K.; Natori, Y.; Fujino, M.; Nishihara, T.; Ikeda, Y.; Nasu, Y.; Saigo, K. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer gene ther., 2008, 15(3), 140-153.
82. Allen, T.M., Cullis, P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Del. Rev., 2013, 65(1), 36-48.
83. Schroeder, A.; Levins, C.G.; Cortez, C.; Langer, R.; Anderson, D.G. Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med., 2010, 267(1), 9-21.
84. Ozpolat, B.; Sood, A.K.; Lopez-Berestein, G. Liposomal siRNA nanocarriers for cancer therapy. Adv. Drug Del. Rev., 2014, 66, 110-116.
85. Felgner, P.L., Ringold, G. Cationic liposome-mediated transfection. Nature, 1989, 337(6205), 387-388.
86. Wolff, J.A., Rozema, D.B. Breaking the bonds: non-viral vectors become chemically dynamic. Mol. Therapy, 2008, 16(1), 8-15.
87. Wan, C.; Allen, T.; Cullis, P. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Del. Trans. Res., 2014, 4(1), 74-83.
88. Tseng, Y.-C.; Mozumdar, S.; Huang, L. Lipid-based systemic delivery of siRNA. Adv Drug Del Rev, 2009, 61(9), 721-731.
89. Chen, Y.; Sen, J.; Bathula, S.R.; Yang, Q.; Fittipaldi, R.; Huang, L. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm., 2009, 6(3), 696-705.
90. Dalby, B.; Cates, S.; Harris, A.; Ohki, E.C.; Tilkins, M.L.; Price, P.J.; Ciccarone, V.C. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods, 2004, 33(2), 95-103.
91. Mo, R.H.; Zaro, J.L.; Ou, J.-H.J.; Shen, W.-C. Effects of Lipofectamine 2000/siRNA complexes on autophagy in hepatoma cells. Mol. Biotechnol., 2012, 51(1), 1-8.
92. Mansoori, B.; Mohammadi, A.; Goldar, S.; Shanehbandi, D.; Mohammadnejad, L.; Baghbani, E.; Kazemi, T.; Kachalaki, S.; Baradaran, B. Silencing of High Mobility Group Isoform IC (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468). 2016.
93. Ma, Z.; Li, J.; He, F.; Wilson, A.; Pitt, B.; Li, S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun., 2005, 330(3), 755-759.
94. Pecot, C.V.; Calin, G.A.; Coleman, R.L.; Lopez-Berestein, G.; Sood, A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer, 2011, 11(1), 59-67.
95. Omidi, Y.; Barar, J.; Akhtar, S. Toxicogenomics of cationic lipidbased vectors for gene therapy: impact of microarray technology. Curr. Drug Del., 2005, 2(4), 429-441.
96. Dokka, S.; Toledo, D.; Shi, X.; Castranova, V.; Rojanasakul, Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res., 2000, 17(5), 521-525.
97. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004, 432(7014), 173-178.
98. DiFiglia, M.; Sena-Esteves, M.; Chase, K.; Sapp, E.; Pfister, E.; Sass, M.; Yoder, J.; Reeves, P.; Pandey, R.K.; Rajeev, K.G. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proceed. Nat. Acad. Sci., 2007, 104(43), 17204-17209.
99. Lee, J.-M.; Yoon, T.-J.; Cho, Y.-S. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed. Res. Int., 2013, 2013.
100. Langel, Ü., Cell-penetrating peptides: methods and protocols. 2015: Humana Press.
101. Wang, F.; Wang, Y.; Zhang, X.; Zhang, W.; Guo, S.; Jin, F. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J. Control. Rel., 2014, 174, 126-136.
102. Sawant, R.R., Torchilin, V.P. Challenges in development of targeted liposomal therapeutics. AAPS J., 2012, 14(2), 303-315.
103. Li, W., Szoka Jr, F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res., 2007, 24(3), 438-449.
104. Woodle, M.C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem. Phys. Lipids, 1993, 64(1), 249-262.
105. Moreira, J.; Santos, A.; Moura, V.; Pedroso de Lima, M.; Simoes, S. Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J. Nanosci. Nanotechnol., 2008, 8(5), 2187-2204.
106. Bao, Y.; Jin, Y.; Chivukula, P.; Zhang, J.; Liu, Y.; Liu, J.; Clamme, J.-P.; Mahato, R.I.; Ng, D.; Ying, W. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. Pharm. Res., 2013, 30(2), 342-351.
107. Belliveau, N.M.; Huft, J.; Lin, P.J.; Chen, S.; Leung, A.K.; Leaver, T.J.; Wild, A.W.; Lee, J.B.; Taylor, R.J.; Tam, Y.K. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Therapy—Nucl. Acids, 2012, 1(8), e37.
108. Seth, S.; Johns, R.; Templin, M.V. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther. Deliv., 2012, 3(2), 245-261.
109. Buyens, K.; De Smedt, S.C.; Braeckmans, K.; Demeester, J.; Peeters, L.; van Grunsven, L.A.; du Jeu, X.D.M.; Sawant, R.; Torchilin, V.; Farkasova, K. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Control. Rel., 2012, 158(3), 362-370.
110. Mishra, S.; Webster, P.; Davis, M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol., 2004, 83(3), 97-111.
111. Dams, E.T.; Laverman, P.; Oyen, W.J.; Storm, G.; Scherphof, G.L.; van der Meer, J.W.; Corstens, F.H.; Boerman, O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 2000, 292(3), 1071-1079.
112. Ishida, T.; Ichihara, M.; Wang, X.; Yamamoto, K.; Kimura, J.; Majima, E.; Kiwada, H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Rel., 2006, 112(1), 15-25.
113. Carmona, S.; Jorgensen, M.R.; Kolli, S.; Crowther, C.; Salazar, F.H.; Marion, P.L.; Fujino, M.; Natori, Y.; Thanou, M.; Arbuthnot, P. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol. Pharm., 2009, 6(3), 706-717.
114. Kolli, S.; Wong, S.-P.; Harbottle, R.; Johnston, B.; Thanou, M.; Miller, A.D. pH-Triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo. Bioconjug. Chem., 2013, 24(3), 314-332.
115. Rossi, J. RNAi therapeutics: SNALPing siRNAs in vivo. Gene. Ther., 2006, 13(7), 583-584.
116. Gomes-da-Silva, L.G.C.; Fonseca, N.A.; Moura, V.; Pedroso de Lima, M.C.; Simões, S.R.; Moreira, J.O.N. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc. Chem. Res., 2012, 45(7), 1163-1171.
117. Geisbert, T.W.; Lee, A.C.; Robbins, M.; Geisbert, J.B.; Honko, A.N.; Sood, V.; Johnson, J.C.; De Jong, S.; Tavakoli, I.; Judge, A. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet., 2010, 375(9729), 1896-1905.
118. Morrissey, D.V.; Lockridge, J.A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol., 2005, 23(8), 1002-1007.
119. Zimmermann, T.S.; Lee, A.C.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M.N.; Harborth, J.; Heyes, J.A.; Jeffs, L.B.; John, M. RNAi-mediated gene silencing in non-human primates. Nature, 2006, 441(7089), 111-114.
120. Akhtar, S., Benter, I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Del. Rev., 2007, 59(2), 164-182.
121. Hollins, A.J.; Omidi, Y.; Benter, I.F.; Akhtar, S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J. Drug Target, 2007, 15(1), 83-88.
122. Sawyers, C. Targeted cancer therapy. Nature, 2004, 432(7015), 294-297.
123. Mitsudomi, T. Advances in target therapy for lung cancer. Jpn. J. Clin. Oncol., 2010, 40(2), 101-106.
124. Wittrup, A., Lieberman, J. Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet., 2015, 16(9), 543-552.
125. Brannon-Peppas, L., Blanchette, J.O., Nanoparticle and targeted systems for cancer therapy. Adv. Drug Del. Rev., 2012, 64, 206-212.
126. Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med., 2012, 63, 185-198.
127. Landesman, Y.; Svrzikapa, N.; Cognetta, A.; Zhang, X.; Bettencourt, B.R.; Kuchimanchi, S.; Dufault, K.; Shaikh, S.; Gioia, M.; Akinc, A. In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence, 2010, 1(1), 16.
128. Haussecker, D. The business of RNAi therapeutics in 2012. Molecular therapy. Nucleic acids, 2012, 1(2), e8.
129. Ozcan, G.; Ozpolat, B.; Coleman, R.L.; Sood, A.K.; Lopez-Berestein, G. Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Del. Rev., 2015.